Theil’s Disease (Glomerulonephritis)

Overview

Glomerulonephritis (often referred to as “Theil’s disease” in older literature) is a group of kidney disorders characterized by inflammation of the glomeruli – the tiny filtering units inside each kidney. When the glomeruli become inflamed, they lose the ability to filter blood efficiently, leading to protein and blood leaking into the urine and, eventually, impaired kidney function.

Glomerulonephritis can be primary (originating in the kidneys) or secondary (caused by systemic diseases such as lupus, diabetes, or infections). The condition affects people of all ages, but certain types are more common in specific age groups:

• Children & adolescents – post‑streptococcal glomerulonephritis (PSGN) is the most frequent.
• Young adults – IgA nephropathy (Berger disease) often presents in the 20‑30‑year‑old range.
• Older adults – membranous nephropathy and focal segmental glomerulosclerosis (FSGS) become more prevalent.

Overall, glomerulonephritis accounts for 5–10 % of all cases of chronic kidney disease (CKD) worldwide, affecting roughly 2–4 million people in the United States alone. The incidence varies by type; for example, IgA nephropathy occurs in about 2–3 per 100,000 persons per year in Europe and North America, whereas PSGN peaks at 5–10 per 100,000 children after streptococcal throat infections.

Symptoms

Symptoms depend on the underlying cause, severity, and how quickly the disease progresses. Many patients experience a combination of the following:

Early/Acute Symptoms

• Hematuria – Pink, cola‑colored, or tea‑colored urine caused by red blood cells leaking into the urine.
• Proteinuria – Foamy or frothy urine due to excess protein.
• Edema – Swelling in the face (especially around the eyes), hands, feet, and ankles caused by fluid retention.
• Hypertension – Elevated blood pressure, sometimes sudden and severe.
• Decreased urine output – Oliguria (less than 400 mL/day) or anuria (near‑absence of urine).
• Pain – Flank or abdominal pain is less common but may occur if there is concurrent kidney infection.
• Fatigue & malaise – Resulting from anemia, uremia, or high blood pressure.

Chronic/Long‑Term Symptoms

• Persistent proteinuria – May progress to nephrotic syndrome (protein >3.5 g/day, severe edema, hypo‑albuminemia, hyperlipidemia).
• Progressive renal insufficiency – Rising creatinine and reduced glomerular filtration rate (GFR).
• Anemia – Due to reduced erythropoietin production.
• Bone disease – Secondary hyperparathyroidism from chronic kidney disease.
• Uremic symptoms – Nausea, loss of appetite, itching, metallic taste, or mental status changes when kidneys fail.

Causes and Risk Factors

Glomerulonephritis does not have a single cause; instead, it results from a cascade of immune‑mediated injury. Below are the main categories:

Immune Complex–Mediated (Post‑Infectious)

• Post‑streptococcal GN – Occurs 1‑3 weeks after a throat or skin infection with Group A streptococcus.
• Infection‑related GN – Hepatitis B, C, HIV, or bacterial endocarditis can trigger immune‑complex deposition.

Autoimmune/Primary Glomerulonephritis

• IgA nephropathy (Berger disease) – Deposition of IgA antibodies in the glomerular mesangium; often triggered by mucosal infections.
• Membranous nephropathy – Autoantibodies target the phospholipase A2 receptor (PLA2R) on podocytes.
• Rapidly progressive GN (crescents) – Includes Goodpasture’s syndrome (anti‑GBM antibodies) and pauci‑immune ANCA‑associated vasculitis.

Secondary to Systemic Diseases

• Systemic lupus erythematosus (lupus nephritis)
• Diabetes mellitus (diabetic nephropathy can present as a GN pattern)
• Vasculitides (e.g., microscopic polyangiitis, granulomatosis with polyangiitis)
• Amyloidosis and sarcoidosis

Risk Factors

• Recent streptococcal infection (especially in children)
• Genetic predisposition – certain HLA types increase susceptibility to IgA nephropathy.
• Ethnicity – Asian and Caucasian populations have higher rates of IgA nephropathy; African‑American patients are more prone to FSGS.
• Existing autoimmune disease (e.g., lupus, rheumatoid arthritis)
• Chronic viral infections (HIV, hepatitis B/C)
• Exposure to certain drugs (e.g., NSAIDs, gold salts, penicillamine) and toxins.

Diagnosis

Accurate diagnosis requires a combination of clinical assessment, laboratory testing, imaging, and often a kidney biopsy.

Laboratory Tests

• Urinalysis – Detects hematuria, proteinuria, red blood cell casts (pathognomonic for GN).
• Quantitative protein measurement – 24‑hour urine protein or spot urine protein‑to‑creatinine ratio.
• Serum creatinine & eGFR – Evaluate renal function.
• Complement levels (C3, C4) – Low C3 suggests post‑infectious or lupus GN; normal complement is typical in IgA nephropathy.
• Autoantibody panels – ANA, anti‑dsDNA (lupus), anti‑GBM, ANCA (c‑ANCA, p‑ANCA); helpful for secondary causes.
• Infectious work‑up – Throat cultures, anti‑streptococcal titers (ASO, anti‑DNAse B), hepatitis serologies, HIV screen.
• Lipid profile – Elevated cholesterol often accompanies nephrotic syndrome.

Imaging

• Renal ultrasound – Assesses kidney size and rules out obstruction; kidneys are often normal or mildly enlarged early in GN.
• CT or MRI – Reserved for complicated cases or when structural abnormalities are suspected.

Kidney Biopsy

The definitive test. A percutaneous needle biopsy provides tissue for light microscopy, immunofluorescence, and electron microscopy, revealing the pattern of injury (e.g., immune‑complex deposits, crescent formation, podocyte effacement). The findings guide specific therapy and prognostication.

Diagnostic Criteria Overview

Finding	Typical in
Red blood cell casts	All types of GN
Low C3 complement	Post‑streptococcal, lupus
Elevated IgA on immunofluorescence	IgA nephropathy
Anti‑PLA2R antibodies	Membranous nephropathy
Anti‑GBM antibodies	Goodpasture’s syndrome

Treatment Options

Treatment is individualized based on the underlying cause, severity of kidney damage, and patient comorbidities. Goals are to control inflammation, reduce protein loss, protect renal function, and manage complications such as hypertension.

General Measures

• Blood pressure control – ACE inhibitors or ARBs are first‑line; they lower intraglomerular pressure and reduce proteinuria.
• Dietary modifications – Sodium restriction (<2 g/day), moderate protein intake (0.8–1 g/kg), and limited saturated fats.
• Fluid management – Adjusted according to edema and kidney function.
• Vaccinations – Influenza, pneumococcal, hepatitis B (especially important for patients on immunosuppressive therapy).

Immunosuppressive Therapy

Condition	Medications	Typical Regimen
IgA nephropathy (moderate‑severe proteinuria)	Prednisone ± azathioprine or mycophenolate	Prednisone 0.5–1 mg/kg/day tapered over 6–12 months
Membranous nephropathy (PLA2R‑positive)	Rituximab or cyclophosphamide + steroids	Rituximab 375 mg/m² weekly ×4 or Cyclophosphamide 2 mg/kg/day + prednisone
Rapidly progressive GN (ANCA‑associated)	IV methylprednisolone pulse → oral prednisone + cyclophosphamide or rituximab	Pulse 0.5–1 g/day ×3 days, then oral 1 mg/kg/day, cyclophosphamide 2 mg/kg/day ×3‑6 months
Lupus nephritis (Class III/IV)	Mycophenolate mofetil or cyclophosphamide + steroids	MMF 2–3 g/day OR cyclophosphatin 0.5 g/m² IV monthly ×6 months
Post‑streptococcal GN (usually self‑limited)	Supportive only; corticosteroids rarely needed	—

Other Therapies

• Plasma exchange (PLEX) – Used for anti‑GBM disease, severe ANCA vasculitis, or refractory cases of rapidly progressive GN.
• Diuretics – Loop diuretics (furosemide) for edema control.
• Lipid‑lowering agents – Statins when LDL >100 mg/dL or per KDIGO guidelines.
• Anticoagulation – Consider in nephrotic syndrome with serum albumin <2.5 g/dL due to high thrombotic risk.

Renal Replacement Therapy

If eGFR falls below ~15 mL/min/1.73 m² or the patient develops refractory fluid/electrolyte issues, dialysis (hemo‑ or peritoneal) or kidney transplantation becomes necessary. Transplant outcomes are generally good; recurrence of GN in the graft depends on the original disease (e.g., IgA nephropathy recurs in ~30 % of transplants).

Living with Theil’s Disease (Glomerulonephritis)

Management does not end at the clinic. Below are practical strategies to help patients maintain kidney health and quality of life.

Daily Self‑Care

• Blood pressure monitoring – Aim for <140/90 mmHg (or <130/80 mmHg if diabetes). Keep a log and share with your clinician.
• Daily weight check – Sudden gain >2 kg may signal fluid retention.
• Urine tracking – Note color changes, foamy appearance, or visible blood.
• Medication adherence – Use pill organizers or smartphone reminders; never stop steroids abruptly.
• Healthy diet – Emphasize fresh fruits, vegetables, whole grains, and low‑sodium cooking methods.
• Exercise – Moderate aerobic activity (30 minutes most days) improves blood pressure and cardiovascular health.
• Avoid nephrotoxins – Over‑the‑counter NSAIDs, contrast dye (unless essential), and excessive herbal supplements.

Psychosocial Support

• Join patient support groups (National Kidney Foundation, American Association of Kidney Patients).
• Consider counseling to cope with chronic illness stress.
• Maintain regular follow‑up appointments; early detection of flares prevents irreversible damage.

Monitoring Schedule

Parameter	Frequency (stable disease)
Blood pressure	Daily at home; office check every visit
Serum creatinine/eGFR	Every 3–6 months (more often if on immunosuppression)
Urine protein/creatinine ratio	Every 3–6 months
Lipid panel	Annually or as directed
Complement & autoantibodies	When disease activity changes

Prevention

Because many forms of glomerulonephritis are immune‑mediated, complete prevention is not always possible, but risk can be reduced:

• Prompt treatment of streptococcal infections – Seek medical care for sore throat or skin sores; complete the prescribed antibiotics.
• Vaccinate – Influenza and pneumococcal vaccines lower infection‑related GN triggers.
• Control systemic diseases – Tight glucose control in diabetes, aggressive lupus management, and hypertension control limit secondary GN.
• Limit exposure to nephrotoxic agents – Use the lowest effective NSAID dose, avoid illicit drugs, and discuss any new supplement with your doctor.
• Regular health screenings – Annual urinalysis for high‑risk groups (family history of IgA nephropathy, systemic lupus).

Complications

If glomerulonephritis is left untreated or inadequately controlled, several serious complications may arise:

• Chronic kidney disease (CKD) & End‑stage renal disease (ESRD) – Approximately 30 % of patients with severe GN progress to ESRD within 10 years (NIH, 2022).
• Nephrotic syndrome complications – Hypercoagulability leading to deep‑vein thrombosis or pulmonary embolism.
• Hypertensive emergencies – Malignant hypertension can cause retinal hemorrhage, stroke, or cardiac failure.
• Infections – Immunosuppressive drugs increase susceptibility to bacterial, viral, and fungal infections.
• Cardiovascular disease – CKD accelerates atherosclerosis; patients have a 2‑3‑fold higher risk of myocardial infarction.
• Bone disease & anemia – Due to reduced erythropoietin and disturbances in calcium‑phosphate metabolism.

When to Seek Emergency Care

---

**References**

• Mayo Clinic. “Glomerulonephritis.” Updated 2023. https://www.mayoclinic.org
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Glomerular Diseases.” 2022. https://www.niddk.nih.gov
• Cleveland Clinic. “IgA Nephropathy (Berger Disease).” 2023. https://my.clevelandclinic.org
• Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Glomerular Diseases. Kidney Int. 2021.
• World Health Organization. “Vaccines and Kidney Disease.” 2022.